Headquartered in San Diego, CA Fiscal year ends December NASDAQ: QDEL quidelortho.com
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of diagnostic solutions with expertise spanning clinical chemistry, immunoassay, immunohematology, molecular testing, and point-of-care diagnostics. The company serves healthcare providers from the point of care to hospital laboratories, offering fast, accurate, and reliable diagnostic results to improve patient outcomes. Its product portfolio includes the Labs segment (clinical chemistry and immunoassay platforms), Immunohematology (blood typing and transfusion medicine), Point of Care (rapid diagnostics including the Triage product line), Molecular Diagnostics, and Donor Screening. QuidelOrtho operates globally with significant revenue exposure to China and other international markets. Updated
Monday's top analyst upgrades and downgrades included Coca-Cola, Datadog, Domino’s Pizza, Enphase Energy, Harley-Davidson, Johnson & Johnson, Liberty Global, Microsoft, Nasdaq, Nike, Tesla and Workday.
Wednesday's top analyst upgrades and downgrades included Bloomin' Brands, ChargePoint, Clorox, Cloudflare, Intel, Novavax, Owens Corning, Palo Alto Networks and PPL.
Tuesday’s top analyst upgrades and downgrades included Bilibili, Carvana, Crocs, GameStop, Goldman Sachs, Nike, Sarepta Therapeutics, Vir Biotechnology and Weber.
Friday's top analyst upgrades and downgrades included Biogen, CME, Dropbox, DocuSign, Nvidia, Ping Identity, Signet Jewelers and Tilray.
Friday's top analyst upgrades and downgrades included AvalonBay Communities, Bristol-Myers Squibb, Carrier, Comcast, CyrusOne, DraftKings, Nvidia and Textron.
Friday's top analyst upgrades and downgrades included Adobe, Ford, Goldman Sachs, Intel, Microsoft, Salesforce.com, Seagate Technology, Snowflake, Targa Resources and Walt Disney.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of diagnostic solutions with expertise spanning clinical chemistry, immunoassay, immunohematology, molecular testing, and point-of-care diagnostics.
24/7 Wall St.'s 12-month price target for QDEL is $15.34, rated Buy. The Wall Street consensus target is $14.67. QDEL price prediction →
